Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 3781525, 5 pages
Clinical Study

Role of FGF23 in Pediatric Hypercalciuria

1Pediatric Nephrology Unit, Clinics Hospital, School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil
2Pediatric Nephrology Unit, The Nephrology Center, Santa Casa de Belo Horizonte Hospital, Belo Horizonte, MG, Brazil
3Bone and Mineral Disorders Clinic, Section of Pediatric Nephrology, Children’s Mercy Hospital and Clinics, University of Missouri at Kansas City, Kansas City, MO, USA

Correspondence should be addressed to Maria Goretti Moreira Guimarães Penido; rb.moc.oohay@odinepitterogairam

Received 14 July 2017; Revised 26 September 2017; Accepted 22 October 2017; Published 31 December 2017

Academic Editor: Peyman Björklund

Copyright © 2017 Maria Goretti Moreira Guimarães Penido et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. This study explored the possible role of FGF23 in pediatric hypercalciuria. Methods. Plasma FGF23 was measured in 29 controls and 58 children and adolescents with hypercalciuria: 24 before treatment (Pre-Treated) and 34 after 6 months of treatment (Treated). Hypercalciuric patients also measured serum PTH hormone, 25(OH)vitD, phosphate, calcium, creatinine, and 24 h urine calcium, phosphate, and creatinine. Results. There were no differences in age, gender, ethnicity, or body mass index either between controls and patients, or between Pre-Treated and Treated patients. Median plasma FGF23 in controls was 72 compared with all patients, 58 RU/mL (). However, whereas FGF23 in Pre-Treated patients, 73 RU/mL, was not different from controls, in Treated patients it was 50 RU/mL, significantly lower than in both controls () and Pre-Treated patients (). In all patients, there was a correlation between FGF23 and urinary calcium (; ). Treated patients had significantly lower urinary calcium (), higher TP/GFR (), and higher serum phosphate () versus Pre-Treated patients. Conclusions. Pharmacological treatment of hypercalciuric patients resulted in significantly lower urinary calcium excretion, lower serum FGF23, and elevated TP/GFR and serum phosphate concentration, without significant changes in PTH. Further studies are indicated. This trial is registered with Clinical Registration Number RBR 8W27X5.